Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus

摘要

The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.

主权项

1. A method of treating a patient diagnosed with an autoimmune disorder having the symptom of accumulation of tingible body macrophages comprising:
administering to said patient an effective amount of an agent, wherein the disorder is selected from the group consisting of systemic lupus erythematosus, drug-induced lupus, neonatal lupus, cutaneous lupus, and rheumatoid arthritis, wherein the agent comprises a peptide comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO: 1; (b) N-terminal truncations of (a); and (c) C-terminal truncations of (a) or (b); and wherein the agent has LPLA2 enzymatic activity.